GOLDEN, Colo. — May 19, 2026 — A growing emphasis on dose-sparing strategies and equitable vaccine access has renewed global interest in ID vaccine delivery. A recent, peer-reviewed publication in Qeios¹ evaluated the evidence on implementation of novel technologies for ID delivery of fractional-dose inactivated polio vaccine (fIPV).
View
GOLDEN, Colo. — May 7, 2026 — PharmaJet, a global leader in needle-free injection technology, today announced that its WHO-prequalified Tropis ID Needle-free Injection System will be used to deliver approximately 1.4 million doses of fractional inactivated polio vaccine (fIPV) during upcoming polio immunization campaigns in Nigeria. PharmaJet is partnering
View
GOLDEN, Colo. — March 24, 2026 — PharmaJet®, a company focused on improving the performance and outcomes of injectables through needle-free injection technology, announced that its partner, Brazilian Tuberculosis Research Network (REDE-TB), plans to initiate a clinical study to evaluate the accuracy, workflow efficiency, safety, and acceptability of the tuberculin
View
GOLDEN, Colo. — January 9, 2026 — PharmaJet®, a company focused on improving the performance and outcomes of injectables through needle-free injection technology, announced that its partner Scancell has reported updated Phase 2 clinical data from the SCOPE study in unresectable advanced melanoma. In this study, Scancell’s iSCIB1+ immunotherapy was
View
GOLDEN, Colo., CAIRO, Egypt — November 6, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that it has signed a Distribution Agreement with ATR, an affiliate to EVA Pharma, the leading pharmaceutical company driving healthcare
View
GOLDEN, Colo. — November 4, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its needle-free injection technology, will present at the American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting, November 9-13, at the Metro Toronto Convention Centre in Toronto, Ontario,
View
PharmaJet® Tropis® Needle-free Injection System selected for Polio Immunization Campaign in Pakistan
GOLDEN, Colo. — October 23, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its innovative needle-free injection technology, today announced that their WHO prequalified Tropis ID Needle-free Injection System will be used in the latest polio immunization campaign in Pakistan, planned for
View
GOLDEN, Colo. — October 21, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its needle-free injection technology, will present at the 15th Annual Partnership Opportunities in Drug Delivery (PODD) conference, October 27-28, at Westin Copley Place in Boston, Massachusetts. The conference brings
View
GOLDEN, Colorado — October 7, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that it is expanding its needle-free injection portfolio with the development of a suite of proprietary, needle-free, self-injector pens. Prototypes of the
View
Load more